

OPTN Ad Hoc Disease Transmission Advisory Committee

Meeting Summary

July 1, 2025

Conference Call

Stephanie Pouch, MD, MS, Chair

Rachel Miller, MD, Vice Chair

Introduction

The OPTN Ad Hoc Disease Transmission Advisory Committee (the Committee) met via WebEx on 07/01/2023 to discuss the following agenda items:

1. Review & Vote: Summary of Evidence on SARS-CoV-2
2. Review & Vote: Summary of Current Evidence and Information- Mpox in Donor Screening and Transplantation

The following is a summary of the Committee's discussions.

1. Review & Vote: Summary of Evidence on SARS-CoV-2

The Committee reviewed updates to the SARS-CoV-2 Summary of Evidence (SOE) document. These updates were developed in collaboration with the Centers for Disease Control and Prevention and are reviewed and revised annually or as needed.

The purpose of the SOE document is to serve as a resource for the community. The recent changes were non-substantive and focused on improving the accuracy and relevance of the literature cited, consolidating information, and enhancing readability. Updates included:

- Streamlining content for clarity and conciseness
- Incorporating analysis and studies referenced in the document
- Updating hyperlinks
- Simplifying language to improve overall accessibility

The Committee was asked whether they support, abstain, or oppose the proposed changes.

Support: 13 Abstain: 0 Oppose: 0

Summary of discussion:

Decision #1: The Committee supported the proposed changes to the Summary of Evidence on SARS-CoV-2.

There were no further discussions.

Next steps:

The SOE SARS-CoV-2 will be submitted to the Health Resources and Services Administration (HRSA) for review and approval to be updated on the OPTN website.

2. Review & Vote: Summary of Current Evidence and Information- Mpox in Donor Screening and Transplantation

The Committee reviewed updates to the Summary of Current Evidence and Information – Mpox in Donor Screening and Transplantation. These updates were developed in collaboration with the Centers for Disease Control and Prevention and are reviewed and revised annually or as needed.

The purpose of the document is to serve as a resource for the community. Similar to previous updates, no substantive changes were made. Revisions included:

- Updated data
- Consolidation of information
- Refreshed hyperlinks
- A comprehensive review for relevance and accuracy

The Committee was asked whether they support, abstain, or oppose the proposed changes.

Support: 13 Abstain: 0 Oppose: 0

Summary of discussion:

Decision #1: The Committee supported the proposed changes to the Summary of Current Evidence and Information- Mpox in Donor Screening and Transplantation.

There were no further discussions.

Next steps:

The SOE and Information- Mpox in Donor Screening and Transplantation will be submitted to HRSA for review and approval to be updated on the OPTN website.

Upcoming Meetings

- July 28, 2025
- August 12, 2025

Attendance

- **Committee Members**
 - Gabriel Maine
 - Dong Lee
 - Riki Graves
 - Gerald Berry
 - Lara Danziger-Isakov
 - Helen Te
 - Tanvi Sharma
 - Rachel Miller
 - Stephanie Pouch
 - Cynthia Fisher
 - Anna Hughart
 - Jas Kaur
 - Fernanda Silveira
- **HRSA Representatives**
 - First Name Last Name
- **CDC Representatives**
 - Sridhar Bassavaraju
 - Ian Kracalik
- **FDA Representatives**
 - Hanh Khuu
 - Irma Sison
- **UNOS Staff**
 - Tamika Watkins
 - Carly Rhyne
 - Lindsay Larkin
- **Other Attendees**